Clinical Trials Logo

Indolent B-cell Lymphoma clinical trials

View clinical trials related to Indolent B-cell Lymphoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06343935 Not yet recruiting - Clinical trials for Indolent B-cell Lymphoma

A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma

Start date: April 30, 2024
Phase: Phase 4
Study type: Interventional

This is a national multicenter, randomized controlled, open, dose-optimized Phase IV study. It is expected to enroll approximately 88 patients with relapsed/refractory indolent B-cell lymphoma. The aim is to evaluate the efficacy and safety of linperlisib in the treatment of patients with relapsed/refractory indolent B-cell lymphoma at two doses/modes of administration (clinically recommended dose/mode and optimized dose/mode).